Companies ›Healthcare ›HIMS.K

HIMS.K — NYSE Pharmaceutical Services

Hims.K

$25,20

Open in Charts → Attach watcher ⌖

— —

USD

Set alert

Last 30 days

1D5D1M3M6MYTD1Y5YMax

Live price chart loads from the market-data widget.

Mcap

5,8B USD

P/E

—

EV / Rev

—

Div yield

—

Op margin

4,5 %

ROE

23,7 %

Net margin

5,5 %

Debt / equity

1,80

Beta

—

52w range

—

Volume

112

Day range

—

Prev close

$25,20

Open

$24,58

Next earnings

2026-10-28

Ex-dividend

—

TR 1Y

—

About

HIMS.K operates in the healthcare facilities and services industry, providing pharmaceuticals and related healthcare services.

Business. HIMS.K is a healthcare company operating within the Healthcare Facilities & Services industry, with primary activities in pharmaceuticals. The firm generates revenue through service-based models typical of the healthcare services sector. Specific details regarding operating segments, headquarters location, and primary stock exchange listings are not available in the provided data. Consequently, the company is described at the industry level without geographic or segment breakdowns.

Classification99 %

SectorHealth Care

Industry groupPharmaceutical Services

Generated · model-assisted

Sell-side consensus

HOLD17 analysts

5 buy12 hold0 sell

Avg 12m price target26,30

Analyst recommendations

17 analysts · consensus Hold

Buy5

Hold12

Sell0

12-month price target

26,30

Consensus of sell-side coverage.

Upcoming events

EarningsQ3 2026 earnings (expected)2026-10-28 · estimated

See all catalysts →

At a glance

Score

—

not yet scored

Valuation

—

valuation pending

Analysts→

Hold

17 analysts · indicative

Ownership→

Nuveen LLC

largest disclosed fund holder

Profitability→

23,7 %

return on equity

Quality

—

not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

No recent newsroom coverage mentioning HIMS.

Sector rotation

Sector1D1Mvs mkt

Materials+2,3 %+6,6 %+1,7 %

Communication Services+2,2 %−5,5 %+1,7 %

Energy+0,6 %+3,3 %+0,0 %

Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %

Information Technology+0,6 %+6,7 %+0,0 %

Consumer Discretionary+0,4 %+7,6 %−0,2 %

Financials−0,4 %−2,7 %−0,9 %

Real Estate−0,7 %+10,9 %−1,3 %

Consumer Staples−0,7 %+2,3 %−1,3 %

Industrials−1,9 %−3,1 %−2,5 %

Utilities−1,9 %+28,2 %−2,5 %

Developing storylines

No tracked sagas currently linked to HIMS.K. Browse all sagas →

Analysis

AI analysis

Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

Opportunity

— missing data

Upcoming catalysts

Scheduled public events. Informational only — not investment advice.

Company
EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
Macro
Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
Macro & political
ElectionSE Swedish Election2026-09-14 · SE
ElectionUS U.S. Midterms2026-11-03 · US
ElectionFR French Legislative2027-06-01 · FR
Congressional trades
CongressLisa McClain — Hims & Hers Health, Inc. Class A2025-08-04 · Republican · MI · Purchase · $1,001 - $15,000

Pre-earnings brief

Briefing · model-assisted

Hims & Hers Health Inc (HIMS.K) has recorded a major modification in its holder profile, marking the first analysis for this ticker. The most significant development is a substantial increase in shareholding by investor ID 587, whose position grew from 3 shares to 34,614 shares as of March 31, 2026. This adjustment was detected on June 20, 2026, and represents a shift in the investor's portfolio weight from negligible levels to 0.000414868247541521%, with the holding value rising to $0.718586 million. This change is notable as it establishes the initial baseline for tracking institutional or significant holder activity for Hims & Hers Health Inc. Prior to this update, there was no prior basis for delta computation regarding holder changes for this specific ticker. The modification reflects a new or significantly expanded stake by a single entity within the company's broader ownership structure. The company's current profile indicates a top holder count of 30, suggesting a distributed ownership base. However, the specific activity of investor ID 587 highlights a concentrated move within this group. With an officer count of 1 and no current analyst coverage or index membership recorded, the company's public financial footprint remains limited in terms of traditional market metrics. The significance of this holder change lies in its role as the first data point for monitoring capital flows into Hims & Hers Health Inc. While the absolute value of the holding is relatively small, the magnitude of the increase from 3 shares to over 34,000 shares signals a deliberate accumulation by this specific investor. This event sets the stage for future analysis of holder trends and potential shifts in market sentiment toward the company.

Signals & dispatch

peak dispatch · —

Composite-score breakdown

Synthesis

Business

HIMS.K is a healthcare company operating within the Healthcare Facilities & Services industry, with primary activities in pharmaceuticals. The firm generates revenue through service-based models typical of the healthcare services sector. Specific details regarding operating segments, headquarters location, and primary stock exchange listings are not available in the provided data. Consequently, the company is described at the industry level without geographic or segment breakdowns.

Classification99 %

SectorHealth Care

Industry groupPharmaceutical Services

AI synthesis

GENERATED

HIMS.K has a market price of $26.70, resulting in a market capitalization of $6.17 billion. The company's price-to-earnings ratio is 48.06, and its price-to-book ratio is 11.41, indicating a premium valuation relative to its book value. The enterprise value to EBITDA ratio is 65.46, suggesting a high valuation relative to its earnings before interest, taxes, depreciation, and amortization.

In terms of profitability, HIMS.K has a return on equity of 23.73% and a return on assets of 5.96%. These figures indicate that the company is generating a relatively high return on its equity but a moderate return on its assets. The company's gross profit margin is 73.8%, and its operating margin is 4.5%, which are key metrics for assessing its profitability.

HIMS.K's revenue is concentrated in the healthcare sector, with no specific geographic breakdown provided in the available data. The company's capital structure includes $972.58 million in long-term debt and $228.62 million in cash and equivalents, resulting in a debt-to-equity ratio of 1.8. The company's liquidity is rated as medium, with a current ratio of 1.9.

The company's growth trajectory is reflected in its revenue of $2.35 billion and net income of $128.37 million. The company's free cash flow is negative at -$59.72 million, indicating that it is not generating sufficient cash from operations to cover its capital expenditures. The company's capital expenditures amounted to $242.59 million, which is a significant investment in its operations.

HIMS.K faces a medium liquidity risk, as indicated by its current ratio of 1.9. The company's risk assessment also highlights a key flag: net cash is negative after subtracting total debt, which suggests potential liquidity constraints. The company's dilution risk is rated as low, with no significant dilution potential identified.

Recent events and filings do not provide specific details on the company's recent activities or strategic initiatives. The company's analyst estimates indicate a mean price target of $26.30, with a median price target of $25.25. The mean recommendation from analysts is 2.71, indicating a generally neutral stance, with 5 buy recommendations and 12 hold recommendations.

Key takeaways

HIMS.K has a high price-to-earnings ratio of 48.06, indicating a premium valuation.
The company's return on equity is 23.73%, suggesting strong profitability relative to its equity.
HIMS.K has a debt-to-equity ratio of 1.8, indicating a leveraged capital structure.
The company's free cash flow is negative at -$59.72 million, indicating cash flow constraints.
Analysts have a generally neutral stance on the company, with a mean recommendation of 2.71.
**margin_outlook_rationale**: The company's gross profit margin of 73.8% and operating margin of 4.5% suggest a stable margin outlook driven by its healthcare services and pharmaceuticals business.
**rd_outlook_rationale**: No specific information is available on the company's research and development outlook.

Bull / Bear case

Generated · model-assisted

— missing data

In focus — financials by report

Valuation

Market price

$25,20

Market cap

$6.17B

Enterprise valueⓘ

$6.91B

P/Eⓘ

—

Non-GAAP P/Eⓘ

—

EV / Revenueⓘ

—

EV / Op incomeⓘ

—

EV / OCFⓘ

23.0x

P / Bⓘ

11.4x

P / Tangible bookⓘ

11.4x

Tangible book

$540.9M

Net cashⓘ

-$744.0M

Current ratioⓘ

1.9

Debt / equityⓘ

1.8

ROAⓘ

6.0%

ROEⓘ

23.7%

Cash conversionⓘ

234.0%

CapEx / revenueⓘ

-10.3%

SBC / revenueⓘ

—

Dilution ratioⓘ

0.0%

Revenue by segment

Business relationships

Business relationships17 disclosed relationships · 1 type · extracted from filings & disclosures

Subsidiaries17

EX21:00102abd31c5EX21:00102abd31c5Subsidiarie97%

EX21:15996190edccEX21:15996190edccSubsidiarie97%

EX21:1a992b5c54b4EX21:1a992b5c54b4Subsidiarie97%

EX21:3dea562e9b78EX21:3dea562e9b78Subsidiarie97%

EX21:3fa13794ada7EX21:3fa13794ada7Subsidiarie97%

EX21:6b4b1629c03bEX21:6b4b1629c03bSubsidiarie97%

EX21:8fc02caebee0EX21:8fc02caebee0Subsidiarie97%

EX21:af7072c3e4d5EX21:af7072c3e4d5Subsidiarie97%

EX21:ba57232d40a4EX21:ba57232d40a4Subsidiarie97%

EX21:bcead832fd55EX21:bcead832fd55Subsidiarie97%

EX21:c277e77e1d0eEX21:c277e77e1d0eSubsidiarie97%

EX21:cd7c79f79103EX21:cd7c79f79103Subsidiarie97%

EX21:ddd80efc964cEX21:ddd80efc964cSubsidiarie97%

EX21:e89639542f3bEX21:e89639542f3bSubsidiarie97%

EX21:eb1b42d7f7dbEX21:eb1b42d7f7dbSubsidiarie97%

EX21:eebbfa53a4a2EX21:eebbfa53a4a2Subsidiarie97%

EX21:f68e74b6d356EX21:f68e74b6d356Subsidiarie97%

Supply chain

— missing data

Peer comparison

Peer comparison7 peers · vs HIMS · multiples and returns

PHG—

PHG.BK

—

P/E

—

— vs self

Div yield

—

— vs self

ROE

—

— vs self

EHC—

Encompass Health Corp

$112,47

11,5B USD

P/E

18,6x

-29,5 vs self

Div yield

0,6 %

— vs self

ROE

23,2 %

-0,5 vs self

BKD—

Brookdale Senior Living Inc

$14,37

3,4B USD

P/E

—

— vs self

Div yield

—

— vs self

ROE

469,6 %

+445,9 vs self

TDOC—

TELADOC HEALTH, INC.

$6,57

1,2B USD

P/E

—

— vs self

Div yield

—

— vs self

ROE

-14,5 %

-38,2 vs self

NTRA—

NATERA, INC.

$270,36

38,6B USD

P/E

—

— vs self

Div yield

—

— vs self

ROE

-8,5 %

-32,2 vs self

NHC—

National Healthcare Corp

—

P/E

—

— vs self

Div yield

—

— vs self

ROE

—

— vs self

PNTG—

Pennant Group Inc

$40,18

1,4B USD

P/E

39,2x

-8,8 vs self

Div yield

—

— vs self

ROE

8,1 %

-15,6 vs self

Market position

Stress test

— missing data

Predictor forecast

Next quarternear-term

Earnings · next quarterconf 45 %

EPS

Consensus EPS

0,54

Predicted surprise

-0,00

Beat probability

45 %

Analysts

Other metrics

Revenue

—

no estimate

Segment revenue

—

no estimate

Margin

—

no estimate

Segment margin

—

no estimate

as of 2026-05-06 · Earnings Surprise V1

Period note: consensus is not fiscal-period-aligned at source — read as consensus vs the last reported actual, not a calibrated same-quarter surprise.

Full fiscal year~1 year ahead

Full fiscal year · our forecast vs guidance vs consensus

Metric	Our forecast	Guidance	Consensus
EPS	—no estimate	—no estimate	0,54
Revenue	—no estimate	—no estimate	2,8B USD
Operating income	—no estimate	—no estimate	153,0M USD

Full-year consensus mean (period as reported by source) · consensus in USD. Company-level full-year forecast and management guidance are not yet modelled at scale — shown as "no estimate", never inferred.

Corporate eventM&A horizon

M&A probabilityconf 3 %

Probability

3 %

Base rate

3 %

Band

—

180-day horizon · target 2027-01-22 · 1,0× base rate

No acquirer candidates identified by the signal model.

Probabilistic model output — not investment advice. · generated 2026-08-04

Options

— missing data

Short squeeze

— missing data

Earnings-call key lines

— missing data

Consensus distribution

sell-side coverage

Recommendation distribution17 analysts

Strong buy0

Buy5

Hold12

Sell0

Strong sell0

12-month price target$26,30 · Median $25,25

Low $18,00High $35,00

Operating income · consensus153,0M USD

EPS surprise

−5,8 %

reported vs consensus · miss

Revenue surprise

−14,9 %

reported vs consensus · miss

Estimate revisions

consensus EPS · 26-week trend

— missing data

Sell-side observations

Low$18,00

Mean$26,30

Median$25,25

High$35,00

Spot$25,20

+4.4 %implied to mean12-month sell-side price targets · ▲ spot

Themes

— missing data

ESG

— missing data

Risk factors

Dilution riskLow

Liquidity riskMedium

Filing-based flags

Net cash is negative after subtracting total debt.

Benchmarks vs cohort

Op Margin4,5 %Above median

Net Margin5,5 %Above P75

ROE23,7 %Above P75

Capex / Rev-10,3 %Bottom quartile

D/E1,80Bottom quartile

Cash Conv2,34Above median

Corporate actions / M&A

M&A probabilityconf —

Probability

3 %

Base rate

3 %

Band

Low

180-day horizon · target 2027-01-22 · 1,0× base rate

No acquirer candidates identified by the signal model.

Corporate actionsNo corporate-action source connected yet — splits, dividends and buyback events are not tracked for this company. Honest-dim (no data fabricated).

FX exposure

— missing data

Comparable transactions

— missing data

Derivatives & instruments

Derivative transactions

Net disposed 779 855 sh45 exercises · 3 grants15 insiders

Okupe OluyemiChief Financial Officer · Stock Option (right to buy) → Class A Common StockDisposed 6 376 @ $5,01exercise · 2026-06-22
Carroll Patrick HarrisonChief Medical Officer · Restricted Stock Unit → Class A Common StockDisposed 3 533exercise · 2026-06-15
Autor Deborah M.Director, Chief Policy Officer · Restricted Stock Unit → Class A Common StockDisposed 32 919exercise · 2026-06-15
Carroll Patrick HarrisonChief Medical Officer · Restricted Stock Unit → Class A Common StockDisposed 9 405exercise · 2026-06-15
Okupe OluyemiChief Financial Officer · Restricted Stock Unit → Class A Common StockDisposed 18 334exercise · 2026-06-15
Okupe OluyemiChief Financial Officer · Restricted Stock Unit → Class A Common StockDisposed 22 988exercise · 2026-06-15
Okupe OluyemiChief Financial Officer · Restricted Stock Unit → Class A Common StockDisposed 11 483exercise · 2026-06-15
Okupe OluyemiChief Financial Officer · Restricted Stock Unit → Class A Common StockDisposed 18 811exercise · 2026-06-15
Chi MichaelChief Operating Officer · Restricted Stock Unit → Class A Common StockDisposed 16 496exercise · 2026-06-15
Carroll Patrick HarrisonChief Medical Officer · Restricted Stock Unit → Class A Common StockDisposed 8 148exercise · 2026-06-15
Carroll Patrick HarrisonChief Medical Officer · Restricted Stock Unit → Class A Common StockDisposed 4 840exercise · 2026-06-15
WELLS DAVID BDirector · Restricted Stock Unit → Class A Common StockDisposed 957exercise · 2026-06-15
Payne Christopher DDirector · Restricted Stock Unit → Class A Common StockDisposed 647exercise · 2026-06-15
Payne Christopher DDirector · Restricted Stock Unit → Class A Common StockDisposed 10 040exercise · 2026-06-15
Carroll Patrick HarrisonChief Medical Officer · Restricted Stock Unit → Class A Common StockDisposed 435exercise · 2026-06-15
Manuel AnjaDirector · Restricted Stock Unit → Class A Common StockDisposed 10 040exercise · 2026-06-15
Dudum AndrewDirector, Chief Executive Officer, 10% owner · Restricted Stock Unit → Class A Common StockDisposed 19 150exercise · 2026-06-15
Chi MichaelChief Operating Officer · Restricted Stock Unit → Class A Common StockDisposed 16 297exercise · 2026-06-15
Chi MichaelChief Operating Officer · Restricted Stock Unit → Class A Common StockDisposed 19 358exercise · 2026-06-15
Chi MichaelChief Operating Officer · Restricted Stock Unit → Class A Common StockDisposed 10 599exercise · 2026-06-15
Chi MichaelChief Operating Officer · Restricted Stock Unit → Class A Common StockDisposed 23 514exercise · 2026-06-15
Becklund IrenePAO · Restricted Stock Unit → Class A Common StockDisposed 2 291exercise · 2026-06-15
Becklund IrenePAO · Restricted Stock Unit → Class A Common StockDisposed 4 065exercise · 2026-06-15
Becklund IrenePAO · Restricted Stock Unit → Class A Common StockDisposed 4 344exercise · 2026-06-15
Becklund IrenePAO · Restricted Stock Unit → Class A Common StockDisposed 1 392exercise · 2026-06-15

Actions

Set alert Open in charts

Ask Handelsavisen

— missing data

Data sources

Market data
Market data cache
Issuer disclosures
Public news
Earnings transcripts
Consensus estimates
ESG data

How metrics are computed

Ev To Operating Cash Flow
enterprise_value / operating_cash_flow
Return On Equity
net_income / total_equity
Price To Earnings
market_price / (net_income / shares_outstanding_diluted)
Price To Book
market_price / (adjusted_book_value / shares_outstanding_diluted)
Dilution Ratio
(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
Market Price
input from market-data provider (delayed close or quote-shim mid)

Source documents

HIMS.K Market data — financials · 2026-05-28
Hims & Hers Health Inc Market data — analyst estimates · 2026-05-28

Ownership & reference

Top holders

Nuveen LLCInvestment Managers · as of 2024-12-310,02 %$70M
UBS Financial Services, Inc.Investment Managers · as of 2026-03-310,02 %$86M
Principal Global Investors (Equity)Investment Managers · as of 2026-03-310,01 %$27M
Morgan Stanley Smith Barney LLCInvestment Managers · as of 2026-03-310,01 %$185M
Vanguard Capital Management, LLCInvestment Managers · as of 2025-12-310,01 %$679M
Charles Schwab Investment Management, Inc.Investment Managers · as of 2026-03-310,01 %$49M
Geode Capital Management, L.L.C.Investment Managers · as of 2026-03-310,01 %$108M
Goldman Sachs Asset Management, L.P.Investment Managers · as of 2026-03-310,01 %$51M
Northern Trust Investments, Inc.Investment Managers · as of 2026-03-310,01 %$51M
BlackRock Institutional Trust Company, N.A.Investment Managers · as of 2024-06-300,01 %$294M
State Street Investment Management (US)Investment Managers · as of 2026-03-310,01 %$155M
AllianceBernstein L.P.Investment Managers · as of 2026-03-310,01 %$16M
Bank of New York Mellon CorpInstitutional Investor · as of 2026-03-310,01 %$28M
First Trust Advisors L.P.Investment Managers · as of 2026-03-310,00 %$6M
Wellington Management Company, LLPInvestment Managers · as of 2026-03-310,00 %$20M
T. Rowe Price Associates, Inc.Investment Managers · as of 2026-03-310,00 %$0M
Raymond James & Associates, Inc.Brokerage Firms · as of 2026-03-310,00 %$10M
Dimensional Fund Advisors, L.P.Investment Managers · as of 2026-03-310,00 %$14M
Wells Fargo AdvisorsBrokerage Firms · as of 2026-03-310,00 %$14M
Invesco QQQ TrustFunds · as of 2026-03-310,00 %$9M
AMERIPRISE FINANCIAL INCInstitutional Investor · as of 2026-03-310,00 %$5M
LPL Financial LLCInvestment Managers · as of 2026-03-310,00 %$5M
Franklin Advisers, Inc.Investment Managers · as of 2026-03-310,00 %$3M
AQR Capital Management, LLCInvestment Managers · as of 2026-03-310,00 %$1M
Victory Capital Management Inc.Investment Managers · as of 2026-03-310,00 %$1M
PNC Investments LLCInvestment Managers · as of 2026-03-310,00 %$1M
American Century Investment Management, Inc.Investment Managers · as of 2026-03-310,00 %$1M
JONES FINANCIAL COMPANIES LLLPInstitutional Investor · as of 2026-03-310,00 %$0M
FMR LLCInstitutional Investor · as of 2026-03-310,00 %$2M
PNC Investments LLCInvestment Managers · as of 2026-03-310,00 %$0M

Leadership

Andrew DudumChairman of the Board, Chief Executive Officer

Insider activity

Net selling1 buys · 7 sellsnet -$2,2M15 insiders · last 365d

Okupe OluyemiChief Financial Officer · Class A Common StockSold 18 197 @ $34,03$619K · 2026-06-22
Okupe OluyemiChief Financial Officer · Class A Common StockOther 6 376 @ $5,01$32K · 2026-06-22
Carroll Patrick HarrisonChief Medical Officer · Class A Common StockSold 23 726 @ $35,00$830K · 2026-06-18
Elshenawy MohamedCTO · Class A Common StockSold 30 040 @ $31,50$946K · 2026-06-17
Chi MichaelChief Operating Officer · Class A Common StockSold 14 027 @ $31,50$442K · 2026-06-17
Becklund IrenePAO · Class A Common StockSold 4 490 @ $31,50$141K · 2026-06-17
Becklund IrenePAO · Class A Common StockSold 7 573 @ $30,25$229K · 2026-06-16
Payne Christopher DDirector · Class A Common StockOther 647 · 2026-06-15
Carroll Patrick HarrisonChief Medical Officer · Class A Common StockOther 25 926 · 2026-06-15
Carroll Patrick HarrisonChief Medical Officer · Class A Common StockOther 8 310 @ $30,17$251K · 2026-06-15
Okupe OluyemiChief Financial Officer · Class A Common StockOther 71 616 · 2026-06-15
Okupe OluyemiChief Financial Officer · Class A Common StockOther 39 541 @ $30,17$1,2M · 2026-06-15
Autor Deborah M.Director, Chief Policy Officer · Class A Common StockOther 32 919 · 2026-06-15
Autor Deborah M.Director, Chief Policy Officer · Class A Common StockOther 15 396 @ $30,17$464K · 2026-06-15
Chi MichaelChief Operating Officer · Class A Common StockOther 86 264 · 2026-06-15
Chi MichaelChief Operating Officer · Class A Common StockOther 47 699 @ $30,17$1,4M · 2026-06-15
Becklund IrenePAO · Class A Common StockOther 15 971 · 2026-06-15
Becklund IrenePAO · Class A Common StockOther 5 870 @ $30,17$177K · 2026-06-15
Boughton SoleilChief Legal Officer · Class A Common StockOther 42 261 · 2026-06-15
Boughton SoleilChief Legal Officer · Class A Common StockOther 23 315 @ $30,17$703K · 2026-06-15
Dudum AndrewDirector, Chief Executive Officer, 10% owner · Class A Common StockOther 154 991 · 2026-06-15
Dudum AndrewDirector, Chief Executive Officer, 10% owner · Class A Common StockOther 85 632 @ $30,17$2,6M · 2026-06-15
Elshenawy MohamedCTO · Class A Common StockOther 282 597 · 2026-06-15
Elshenawy MohamedCTO · Class A Common StockOther 151 534 @ $30,17$4,6M · 2026-06-15
WELLS DAVID BDirector · Class A Common StockOther 957 · 2026-06-15

Short positioning

61.4Mshares short+0.4% vs prior

4.52days to cover

46.8%short of daily vol

28.1Kfails-to-deliver

as of 2026-07-15 · short-interest report (free)

Geographic breakdown

— missing data

Listings · one canonical issuer all listings resolve to the canonical

HIMS.KCanonical

NYSE · USD

Intel & risk

PredictorBeat prob45 %Surprise-0,00M&A prob3 %Full forecast →

peak dispatch · —

OSINT findings

Dilution riskLow

Liquidity riskMedium

Net cash is negative after subtracting total debt.

Relationship graph

This companySectorSubsidiaries

Evidence & claims

From filings & derived data

Total assets (YoY) (2025-12-31 vs 2024-12-31): 204.5%Derived (calculated)
Operating income (YoY) (2025-12-31 vs 2024-12-31): 70.6%Derived (calculated)
Revenue (YoY) (2025-12-31 vs 2024-12-31): 59.0%Derived (calculated)
Shareholders' equity (YoY) (2025-12-31 vs 2024-12-31): 13.5%Derived (calculated)
Total liabilities (YoY) (2025-12-31 vs 2024-12-31): 599.1%Derived (calculated)
Cost of revenue (YoY) (2025-12-31 vs 2024-12-31): 102.5%Derived (calculated)
EPS (basic) (YoY) (2025-12-31 vs 2024-12-31): -1.7%Derived (calculated)
EPS (diluted) (YoY) (2025-12-31 vs 2024-12-31): -3.8%Derived (calculated)
Gross profit (YoY) (2025-12-31 vs 2024-12-31): 47.8%Derived (calculated)
Net income (YoY) (2025-12-31 vs 2024-12-31): 1.8%Derived (calculated)
Operating cash flow (YoY) (2025-12-31 vs 2024-12-31): 19.5%Derived (calculated)
Net margin (FY 2025-12-31): 5.5%Derived (calculated)
Gross margin (FY 2025-12-31): 73.8%Derived (calculated)
Return on equity (FY 2025-12-31): 23.7%Derived (calculated)
Return on assets (FY 2025-12-31): 6.0%Derived (calculated)
Current ratio (FY 2025-12-31): 1.90xDerived (calculated)
Debt-to-equity (FY 2025-12-31): 2.98xDerived (calculated)
Cash & equivalents (YoY) (2025-12-31 vs 2024-12-31): 3.6%Derived (calculated)
Pre-tax income (annual): USD 123.92MSEC XBRL filing
Shareholders' equity (annual): USD 540.93MSEC XBRL filing
Current assets (annual): USD 767.64MSEC XBRL filing
Total operating expenses (annual): USD 1.63BSEC XBRL filing
Total assets (annual): USD 2.15BSEC XBRL filing
Operating cash flow (annual): USD 300.01MSEC XBRL filing

Showing 24 of 54 surfaced claims.

Atomic claims from regulatory filings and derived calculations. Provenance shown as source kind only.

The Thread

Everything we know, in order

2026-10-28EVENTUpcomingQ3 2026 earnings (expected) estimated date

2026-06-30 03:38 UTCEARNINGSUpcomingForecast: insider_flow_signal (90d)

2026-06-30 03:38 UTCEARNINGSUpcomingForecast: earnings_forecast (90d)

2026-06-30 03:38 UTCEARNINGSUpcomingForecast: ma_probability (180d)

2026-06-27 03:14 UTCHOLDERInstitutional holding changed

2026-06-27 03:14 UTCHOLDER1 institutional position change flagged (1 major)

2026-06-22 00:00 UTCINSIDER81 insider transactions — 2026-06 · net sell $13.2M 44 derivative

2026-06-22INSIDEROkupe Oluyemi sold 18.2k sh Class A Common Stock — Chief Financial Officer ~$619k

2026-06-22INSIDEROkupe Oluyemi transacted 6.4k sh Class A Common Stock — Chief Financial Officer ~$32k

2026-06-22INSIDEROkupe Oluyemi disposed of 6.4k sh Stock Option (right to buy) — Chief Financial Officer

2026-06-21 02:57 UTCHOLDERInstitutional holding changed

2026-06-21 02:57 UTCHOLDER1 institutional position change flagged (1 major)

2026-06-18INSIDERCarroll Patrick Harrison sold 23.7k sh Class A Common Stock — Chief Medical Officer ~$830k

2026-06-17INSIDERElshenawy Mohamed sold 30.0k sh Class A Common Stock — CTO ~$946k

2026-06-17INSIDERChi Michael sold 14.0k sh Class A Common Stock — Chief Operating Officer ~$442k

2026-06-17INSIDERBecklund Irene sold 4.5k sh Class A Common Stock — PAO ~$141k

2026-06-16INSIDERBecklund Irene sold 7.6k sh Class A Common Stock — PAO ~$229k

2026-06-15FILING8-K filing →

2026-06-15INSIDERPayne Christopher D transacted 647 sh Class A Common Stock — Director

2026-06-15INSIDERCarroll Patrick Harrison transacted 25.9k sh Class A Common Stock — Chief Medical Officer

2026-06-15INSIDERCarroll Patrick Harrison transacted 8.3k sh Class A Common Stock — Chief Medical Officer ~$251k

2026-06-15INSIDEROkupe Oluyemi transacted 71.6k sh Class A Common Stock — Chief Financial Officer

2026-06-15INSIDEROkupe Oluyemi transacted 39.5k sh Class A Common Stock — Chief Financial Officer ~$1.19M

2026-06-15INSIDERAutor Deborah M. transacted 32.9k sh Class A Common Stock — Director, Chief Policy Officer

2026-06-15INSIDERAutor Deborah M. transacted 15.4k sh Class A Common Stock — Director, Chief Policy Officer ~$464k

2026-06-15INSIDERChi Michael transacted 86.3k sh Class A Common Stock — Chief Operating Officer

2026-06-15INSIDERChi Michael transacted 47.7k sh Class A Common Stock — Chief Operating Officer ~$1.44M

2026-06-15INSIDERBecklund Irene transacted 16.0k sh Class A Common Stock — PAO

2026-06-15INSIDERBecklund Irene transacted 5.9k sh Class A Common Stock — PAO ~$177k

2026-06-15INSIDERBoughton Soleil transacted 42.3k sh Class A Common Stock — Chief Legal Officer

2026-06-15INSIDERBoughton Soleil transacted 23.3k sh Class A Common Stock — Chief Legal Officer ~$703k

2026-06-15INSIDERDudum Andrew transacted 155.0k sh Class A Common Stock — Director, Chief Executive Officer, 10% owner

2026-06-15INSIDERDudum Andrew transacted 85.6k sh Class A Common Stock — Director, Chief Executive Officer, 10% owner ~$2.58M

2026-06-15INSIDERElshenawy Mohamed transacted 282.6k sh Class A Common Stock — CTO

2026-06-15INSIDERElshenawy Mohamed transacted 151.5k sh Class A Common Stock — CTO ~$4.57M

2026-06-15INSIDERWELLS DAVID B transacted 957 sh Class A Common Stock — Director

2026-06-15INSIDEROkupe Oluyemi disposed of 18.3k sh Restricted Stock Unit — Chief Financial Officer

2026-06-15INSIDEROkupe Oluyemi disposed of 23.0k sh Restricted Stock Unit — Chief Financial Officer

2026-06-15INSIDERChi Michael disposed of 16.5k sh Restricted Stock Unit — Chief Operating Officer

2026-06-15INSIDEROkupe Oluyemi disposed of 11.5k sh Restricted Stock Unit — Chief Financial Officer

Showing the 40 most recent of 63 entries.

The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.

Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage

Analyst recommendations

At a glance

What drives this business

News & coverage

Sector rotation

Developing storylines

Analysis

Opportunity

Upcoming catalysts

Pre-earnings brief

Signals & dispatch

Composite-score breakdown

Synthesis

Bull / Bear case

In focus — financials by report

Valuation

Revenue by segment

Market share

Business relationships

Supply chain

Peer comparison

Market position

Stress test

Predictor forecast

Options

Short squeeze

Earnings-call key lines

Consensus distribution

Estimate revisions

Sell-side observations

Themes

ESG

Risk factors

Benchmarks vs cohort

Corporate actions / M&A

FX exposure

Comparable transactions

Derivatives & instruments

Derivative transactions

Actions

Ask Handelsavisen

Ownership & reference

Top holders

Leadership

Insider activity

Short positioning

Geographic breakdown

Intel & risk

Evidence & claims

The Thread